NCT07156201View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

PHASE1RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
KCNT1-Related Epilepsy
Interventions
DRUG

ABS-1230

ABS-1230

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

Scientia Clinical Research, Sydney

Sponsors
All Listed Sponsors
lead

Actio Biosciences, Inc.

INDUSTRY

NCT07156201 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years | Biotech Hunter | Biotech Hunter